Enzalutamide: looking back at its preclinical discovery

Area of Science:

• Oncology
• Pharmacology
• Prostate Cancer Research

Background:

• Metastatic prostate cancer (PCa) typically treated with castration therapy eventually leads to castration-recurrent PCa (CRPC).
• Enzalutamide, a second-generation androgen receptor (AR) antagonist, offers an alternative therapy for patients with CRPC.
• It functions by inhibiting AR nuclear translocation and DNA binding without agonist activity.

Purpose of the Study:

• To review the history, discovery, and preclinical results of enzalutamide.
• To discuss resistance mechanisms and clinical development of enzalutamide.
• To highlight post-launch developments and future therapeutic strategies.

Main Methods:

• Literature review of enzalutamide's history and mechanism of action.
• Analysis of preclinical experimental data, including resistance mechanisms.
• Examination of clinical trial data and post-market surveillance.

Main Results:

• Enzalutamide demonstrated a rapid FDA approval timeline (< 6 years) due to its targeted mechanism.
• The drug shows promising efficacy and good tolerability in CRPC patients.
• Drug resistance is a significant limitation, necessitating further research.

Conclusions:

• Enzalutamide represents a significant advancement in CRPC treatment by targeting the androgen-AR axis.
• Despite its benefits, the emergence of drug resistance is a critical challenge.
• Future research should explore combinational or sequential enzalutamide therapies to overcome resistance and improve patient outcomes.